A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

Genentech

Status and phase: Completed; Phase 1

Conditions: Diabetes Mellitus, Type 2; Non-Alcoholic Fatty Liver Disease

Treatments: Drug: BFKB8488A; Other: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03060538

GC39547

Details and patient eligibility

About

This is a Phase Ib, randomized, blinded, placebo-controlled, multiple ascending-dose study of the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of BFKB8488A in participants with Type 2 diabetes mellitus (T2DM) and participants with non-alcoholic fatty liver disease(NAFLD). A maximum of approximately 160 participants will be enrolled across multiple sites in the United States. Participants will be randomly assigned to receive study drug (active BFKB8488A or placebo). The study will consist of a screening period (up to 8 weeks), a 12-week treatment period, and a 6-week follow-up period. Participants may come to clinic for an optional pre-screening visit.

Enrollment: 154 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

For T2DM Cohort only:

• Body mass index (BMI) ≥ 27 kg/m2 and ≤ 40 kg/m2.
• A confirmed diagnosis of Type 2 diabetes ≥ 6 months at screening
• Current stable treatment (at least 3 months) for diabetes
• Hemoglobin A1c (HbA1c) ≥ 6.8% and ≤ 9.0%.
• For women of childbearing potential, agreement to remain abstinent or use reliable contraception during treatment period and for at least 42 days after last dose of study drug
• For men, agreement to remain abstinent or use reliable contraception and agree to refrain from donating sperm
• For NAFLD cohort only:
• BMI ≥ 25 kg/m2 and ≤ 40 kg/m2
• At screening, confirmed liver fat by ultrasound OR calculated Liver Fat ≥ 10% using variables from the NAFLD liver fat score
• Hepatic steatosis on magnetic resonance imaging (MRI; ≥ 10% average liver proton density fat fraction [PDFF]) prior to randomization.

Exclusion criteria

• Pregnant, lactating, or intending to become pregnant within 42 days after the last dose of study drug is administered
• Suspected or confirmed diagnosis of Type 1 diabetes
• Significant cardiac disease
• Any psychiatric illness that increases the risk of participation in the study
• History of severe allergic, anaphylactic, or other hypersensitivity reactions, or severe systemic bacterial, fungal, or parasitic infections
• Poor peripheral venous access
• Received blood products within 2 months before dosing
• Donation or loss of blood within 30-56 days prior to study drug administration
• Positive for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody
• Liver enzymes greater than acceptable limits
• History of eating disorders or surgical procedures for weight loss
• Active participation in a structured weight loss or dietary program
• Treatment with investigational therapy or exposure to any biological therapy
• Illicit drug use, marijuana use, or alcohol abuse
• Current use of more than one pack of cigarettes a day or equivalent nicotine- containing products
• Any serious medical condition or abnormality in clinical laboratory tests

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

154 participants in 2 patient groups, including a placebo group

Multiple Ascending Dose BFKB8488A

Experimental group

Description:

Participants will be randomized to receive BFKB8488A. When adequate safety data are available, a review will be done for all participants to make a dose-escalation or dose and/or regimen modification decision. This will be repeated for each cohort.

Treatment:

Drug: BFKB8488A

Placebo

Placebo Comparator group

Description:

Participants will receive BFKB8488A-matching placebo.

Treatment:

Other: Placebo